2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108035
    (-)-JM-1232 1013427-48-9 98%
    (-)-JM-1232 (MR04A3) targets GABA A receptors and exerts its analgesic effects by binding to the benzodiazepine binding site of GABA A receptors. (-)-JM-1232 demonstrates potent analgesic effects in mice against acute thermal stimuli, mechanically induced pain, and visceral pain, with CI50 values of 2.96, 3.06, and 2.27 mg/kg, respectively. (-)-JM-1232 can be used in research related to pain and analgesia.
    (-)-JM-1232
  • HY-108048
    Desoxypeganine 495-59-0 98%
    Desoxypeganine (Deoxypeganine), an alkaloid, is a potent and orally active cholinesterase (BChE and AChE) and selective MAO-A inhibitor, with IC50 values of 2, 17, and 2 μM, respectively. Desoxypeganine can be used for alcohol abuse research.
    Desoxypeganine
  • HY-10805S
    Almorexant-13C,d3 98%
    Almorexant-13C,d3 is the 13C- and deuterium labeled Almorexant. Almorexant (ACT 078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM, respectively.
    Almorexant-13C,d3
  • HY-108227
    Quetiapine sulfone 329216-65-1 98%
    Quetiapine sulfone is a main metabolite of Quetiapine (HY-14544). Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist.
    Quetiapine sulfone
  • HY-108229
    6β-Naltrexol 49625-89-0 98%
    6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit.
    6β-Naltrexol
  • HY-108236
    Naxagolide hydrochloride 99705-65-4 98%
    Naxagolide hydrochloride is an agonist of D2. Naxagolide hydrochloride can be used in study Parkinsonism.
    Naxagolide hydrochloride
  • HY-108242
    Apomorphine hydrochloride 314-19-2 ≥99.0%
    Apomorphine ((-)-Apomorphine) hydrochloride is an orally active agonist of Dopamine receptor. Apomorphine hydrochloride can be used in study Parkinson, biphasic dyskinesias, urinary dysfunction, dystonia, dyspnoea, anismus and belching.
    Apomorphine hydrochloride
  • HY-108248
    KU-32 956498-70-7 98%
    KU-32 is a novel, novobiocin-based Hsp90 inhibitor that can protect against neuronal cell death.
    KU-32
  • HY-108327
    PF-05020182 1354712-92-7 98%
    PF-05020182 is an orally active opener for Kv7 channel, that activates human Kv7.2/7.3, Kv7.4 and Kv7.3/7.5 with EC50 of 334, 625 and 588 nM, respectively. PF-05020182 exhibits anticonvulsant activity in rats corneal electric shock-induced tonic seizure (MES) models. PF-05020182 is blood-brain barrier (BBB) penetrable.
    PF-05020182
  • HY-108340
    PF-06767832 1859081-58-5 98%
    PF-06767832 is a potent muscarinic M1 selective positive allosteric modulator (PAM), with the EC50 of 60 nM. PF-06767832 has good brain penetration.
    PF-06767832
  • HY-108400
    SCH-23390 maleate 87134-87-0 98%
    SCH-23390 maleate (R-(+)-SCH-23390 maleate) is a potent and selective dopamine D1-like receptor antagonist with Kis of 0.2 nM and 0.3 nM for the D1 and D5 receptor, respectively. SCH-23390 maleate is a potent and high efficacy human 5-HT2C receptor agonist with a Ki of 9.3 nM. SCH-23390 maleate also binds with high affinity to the 5-HT2 and 5-HT1C receptors. SCH-23390 maleate inhibits G protein-coupled inwardly rectifying potassium (GIRK) channels with an IC50 of 268 nM.
    SCH-23390 maleate
  • HY-108438
    TCS 2210 1201916-31-5 98%
    TCS 2210 (compound 1) is a neuronal differentiation inducer in mesenchymal stem cells (MSCs). TCS 2210 increases expression of the neuronal markers β-III tubulin and neuron-specific enolase (NSE).
    TCS 2210
  • HY-108455
    N-Palmitoyl dopamine 136181-87-8 98%
    N-Palmitoyl dopamine (PALDA) is a endogenous, long-chain, linear fatty acid dopamide, which is inactive on TRPV1. N-Palmitoyl dopamine displays 'entourage' effects on endovanilloids N-arachidonoyl-dopamine (NADA) and anandamide.
    N-Palmitoyl dopamine
  • HY-108461
    TRPM8-IN-1 1159996-20-9 98%
    TRPM8-IN-1 (example 14) is an inhibitor of transient receptor potential melastatin-8 (TRPM8) channels, IC50<5 μM.
    TRPM8-IN-1
  • HY-108480
    SDZ NKT 343 180046-99-5 98%
    SDZ NKT 343 is a selective, orally active NK1 receptor antagonist with an IC50 of 0.62 nM against human NK1 receptor. SDZ NKT 343 has good analgesic activity.
    SDZ NKT 343
  • HY-108483
    RP 67580 135911-02-3 98%
    RP 67580 is a non-peptide antagonist of substance P (SP), competitively inhibits the binding of [3H]SP to neurokinin receptor 1 (NK1 receptor) in rat brain membranes with a Ki value of 4.16 nM. RP 67580 is a specific antagonist of NK1 receptors and can be used in the research of pain and neurogenic inflammation.
    RP 67580
  • HY-108501
    (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 208706-12-1 98%
    (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 is a selective non-peptide human somatostatin receptor subtype 2 (sst2) agonist. (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 can be used in the study of retinal neuromodulation.
    (1R,1'S,3'R/1R,1'R,3'S)-L-054,264
  • HY-108514
    (±)-PPCC hemioxalate 932736-91-9 98%
    (±)-PPCC hemioxalate is a compound that has the ability to regulate the activity of the sigma-1 receptor. (±)-PPCC hemioxalate can selectively bind sigma-1 protein (s1), and then activate s1 receptor leading to dissociation of s1-BIP complex to regulate ER-mitochondrial calcium signaling, which plays an important role in cell bioenergy and cell survival. (±)-PPCC hemioxalate can be used to study sigma-1 receptors in cocaine addiction, forgetting, pain, depression, Alzheimer's disease, stroke, and cancer.
    (±)-PPCC hemioxalate
  • HY-108546
    L-AP3 23052-80-4 98%
    L-AP3, metabotropic glutamate receptor (mGluR) antagonist, inhibits D-phosphoserine and L-phosphoserine with IC50s of 368 μM and 2087 μM, respectively.
    L-AP3
  • HY-108574
    CP 339818 hydrochloride 478341-55-8 99.61%
    CP 339818 hydrochloride is a nonpeptide and selective Kv1.3 (IC50 value of ~200 nM) blocker. CP 339818 hydrochloride also inhibits Kv1.4 channels. CP 339818 hydrochloride is a significantly less potent blocker of Kv1.1, Kv1.2, Kv1.5, Kv1.6, Kv3.1-4, and Kv4.2. CP 339818 hydrochloride potently blocks the C-type inactivated conformation of Kv1.3 and suppresses T cell activation.
    CP 339818 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity